Breaking News, Collaborations & Alliances

Plus Therapeutics Initiates Manufacturing Activities, Tech Transfer With SpectronRx

The conditions of the previously executed master services agreement support late-stage clinical manufacturing of Rhenium-186 and Reyobiq.

Author Image

By: Patrick Lavery

Content Marketing Editor

Plus Therapeutics is initiating manufacturing activities and technology transfer with SpectronRx, under terms of a previously executed master services agreement. As a healthcare company, Plus develops and commercializes precision diagnostics and radiopharmaceuticals to treat central nervous system (CNS) cancers. Manufacturing and Tech Transfer Specs The agreement supports late-stage clinical manufacturing of Rhenium-186 and Reyobiq. The latter of those (rhenium Re186 obisbemeda) is a novel...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters